Lonza Group AG

Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024

Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates

Lonza Nominates David Meline as Independent Board Member

Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche

Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)

Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds